Journal
VACCINE
Volume 25, Issue 33, Pages 6164-6166Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.06.004
Keywords
13-valent; pneumococcal; conjugate; vaccine; adult; immunogenicity; IgG; opsonophagocytic; reactogenicity; safety
Categories
Ask authors/readers for more resources
In a Phase I study, 15 healthy subjects were randomized to receive a 13-valent pneumococcal conjugate vaccine (PCV 13) and 15 to receive a 23-valent pneumococcal polysaccharide vaccine (23vPS). Antibody responses were measured immediately before and approximately one month after vaccination. Serotype-specific antibodies were measured using an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) and an opsonophagocytic assay (OPA) for functional antibodies. PCV13 was as immunogenic or more immunogenic than 23vPS and was well tolerated. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available